Powder: -20°C for 3 years | In solvent: -80°C for 1 year
B-AP15 (NSC-687852) 是 26S 蛋白酶体的去泛素化酶 Usp14 和 UCHL5 的选择性抑制剂。 它阻断 26S 蛋白酶体的去泛素化活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 187 | 现货 | ||
5 mg | ¥ 352 | 现货 | ||
10 mg | ¥ 597 | 现货 | ||
25 mg | ¥ 1,230 | 现货 | ||
50 mg | ¥ 1,890 | 现货 | ||
100 mg | ¥ 2,890 | 现货 | ||
200 mg | ¥ 4,270 | 现货 | ||
500 mg | ¥ 6,830 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 352 | 现货 |
产品描述 | B-AP15 (NSC-687852)(NSC-687852) is a selective inhibitor of the deubiquitinating enzymes Usp14 and UCHL5 of the 26S proteasome. It blocks the deubiquitinating activity of the 26S proteasome. |
靶点活性 | UCHL5:2.1 μM |
体外活性 | 在HCT-116结肠癌移植瘤的小鼠中,B-AP15(5 mg/kg)可使肿瘤发病显著延缓.对携带鳞状细胞癌移植瘤的重症联合免疫缺陷小鼠,B-AP15(5 mg/kg)可产生显著的抗肿瘤活性. |
体内活性 | 作为UPS抑制剂,通过诱导cathepsin-D依赖性的溶酶体凋亡途径,B-AP15可诱导细胞死亡。与外周血单核细胞或永生化上皮细胞(hTERT-RPE1)相比,B-AP15对HCT-116细胞毒性更大。B-AP15剂量依赖性地使UbG76V-YFP受体累积(IC50:0.8 μM),表明损伤的蛋白酶体降解受损。作用于人类结肠癌HCT-116细胞时,B-AP15(1 μM)可使多聚泛素化蛋白快速累积。B-AP15(1 μM)对ATP诱导的IL-1β从脂多糖诱导的腹腔巨噬细胞中释放有抑制作用。作用于THP-1细胞,B-AP15(1 μM)可使尼日利亚菌素诱导的细胞死亡水平降低。B-AP15(1 μM)处理脂多糖诱导的THP-1细胞,可使尼日利亚菌素处理后形成的ASC斑点数量显著减少。作用于HCT-116细胞,B-AP15(1 μM)使细胞周期在G2/M期停滞,并造成细胞周期抑制剂累积。作用于HCT-116细胞, B-AP15(2.2 μM)使细胞周期蛋白依赖性激酶CDKN1A和CDKNIB,及肿瘤抑制基因TP53的数量剂量依赖性地提高,但不影响鸟氨酸脱羧酶1的数量。 |
激酶实验 | For deubiquitinase inhibition assays, 19S regulatory particle (5 nM), 26S (5 nM) UCH-L1 (5 nM), UCH-L3 (0.3 nM), USP2CD (5 nM) USP7CD (5 nM) USP8CD (5 nM) or BAP1 (5 nM) is incubated with DMSO or b-AP15 and monitored the cleavage of ubiquitin-AMC (1,000 nM) using a Wallac VICTOR Multilabel counter or a Tecan Infinite M1000 equipped with 380 nm excitation and 460 nm emission filters[1]. |
细胞实验 | b-AP15 is dissolved in DMSO and stored, and then diluted with appropriate medium before use[2]. Cell viability is monitored by either the fluorometric microculture cytotoxicity assay or the MTT assay. For the MTT assay, cells are seeded into 96-well flat-bottomed plates overnight and exposed to drugs, using DMSO as the control. At the end of incubations, 10 μl of a stock solution of 5 mg/mL MTT is added into each well, and the plates are incubated 4 hours at 37°C. Formazan crystals are dissolved with 100 μL 10% SDS/10 mM HCl solution overnight at 37°C. Absorbance is measured using an enzyme-linked immunosorbent assay (ELISA) plate reader at 590 nm[2]. |
别名 | NSC 687852 |
分子量 | 419.39 |
分子式 | C22H17N3O6 |
CAS No. | 1009817-63-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 41.9 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3844 mL | 11.9221 mL | 23.8442 mL | 59.6104 mL |
5 mM | 0.4769 mL | 2.3844 mL | 4.7688 mL | 11.9221 mL | |
10 mM | 0.2384 mL | 1.1922 mL | 2.3844 mL | 5.961 mL | |
20 mM | 0.1192 mL | 0.5961 mL | 1.1922 mL | 2.9805 mL | |
50 mM | 0.0477 mL | 0.2384 mL | 0.4769 mL | 1.1922 mL | |
100 mM | 0.0238 mL | 0.1192 mL | 0.2384 mL | 0.5961 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
B-AP15 1009817-63-3 Apoptosis Cell Cycle/Checkpoint DNA Damage/DNA Repair Ubiquitination DUB Deubiquitinase Inhibitor BAP15 inhibit NSC-687852 DUBs B AP15 NSC 687852 b-AP15 B-AP-15 NSC687852 inhibitor